Advertisement

Cefepime challenge after piperacillin/tazobactam-induced thrombocytopenia

  • Caroline BeaulieuEmail author
  • Lisa Kurczewski
  • Vishal Yajnik
Article

Abstract

Drug-induced thrombocytopenia (DITP) has been described as a sudden and severe hematologic complication of piperacillin/tazobactam. The proposed mechanism by which piperacillin/tazobactam causes DITP involves the formation of a covalent bond to platelet membrane protein thereby inducing a humoral immune response. Given the immunogenic nature of this adverse event and the structural similarities across beta-lactam antibiotics, the potential for cross-reactivity between agents within the class should be considered. However, the structural moiety of piperacillin/tazobactam responsible for this immunogenic response has not been identified—the relationship between structure and activity for this phenomenon remains unknown. Data on the safety and cross-reactivity of other beta-lactam agents in this setting is lacking. We report the first case of piperacillin/tazobactam DITP successfully challenged by the use of cefepime for the treatment of aspiration pneumonia. Further studies are needed to determine the structural moiety of piperacillin/tazobactam responsible for this immunogenic response and evaluate the safety of other beta-lactam antibiotics in this clinical setting.

Keywords

Beta-lactams Cefepime Cross reactions Piperacillin Thrombocytopenia 

Notes

Author contribution

V. Yajnik, L. Kurczewski, and C. Beaulieu are the primary contributors to the article and idea development. V. Yajnik, L. Kurczewski, and C. Beaulieu are the primary providers of the patient cases and contributed to the editorial revisions of the article.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

Conflict of interest

V. Yajnik, L. Kurczewski and C. Beaulieu declare that they have no conflict of interest.

Ethical statement

The patient is deceased and did not have mental or physical capacity to provide signed consent at any point during their care due to their medical condition. Given the circumstances, we took additional steps to protect the patient’s privacy and anonymize the manuscript to the greatest possible extent. Furthermore, all information has been de-identified and unique characteristics have been excluded.

References

  1. 1.
    Moreau D, Timsit JF, Vesin A, Garrouste-Orgeas M, de Lassence A, Zahar JR et al (2007) Platelet count decline, an early prognostic marker in critically ill patients with prolonged ICU stays. Chest 131:1735–1740CrossRefGoogle Scholar
  2. 2.
    Strauss R, Wehler M, Mehler K, Kreutzer D, Koebnick C, Hahn EG (2002) Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome. Crit Care Med 30:1765–1771CrossRefGoogle Scholar
  3. 3.
    McMillan R (2007) Hemorrhagic disorders: abnormalities of platelet and vascular function. In: Goldman L, Ausiello D (eds) Cecil medicine, 23rd edn. Saunders Elsevier, Philadelphia, pp 1289–1300Google Scholar
  4. 4.
    Janz TG, Hamilton GC (2006) Disorders of hemostasis. In: Marx J (ed) Rosen’s emergency medicine: concepts and clinical practice, 7th edn. Mosby Elsevier, Philadelphia, pp 1578–1589Google Scholar
  5. 5.
    Aster RH, Bougie DW (2007) Drug-induced immune thrombocytopenia. N Engl J Med 357:580–587CrossRefGoogle Scholar
  6. 6.
    Visentin GP, Liu CY (2007) Drug-induced thrombocytopenia. Hematol Oncol Clin North Am 21:685–696CrossRefGoogle Scholar
  7. 7.
    Boyce K, Brar H, Stabler SN (2016) Piperacillin/tazobactam-induced immune-mediated thrombocytopenia in the intensive care unit. J Clin Pharm Ther 41:730–732CrossRefGoogle Scholar
  8. 8.
    Nguyen VD, Tourigny JF, Roy R, Brouillette D (2015) Rapid-onset thrombocytopenia following piperacillin-tazobactam reexposure. Pharmacotherapy 35:326–330CrossRefGoogle Scholar
  9. 9.
    Shaik S, Kazi HA, Ender PT (2015) Rapid-onset piperacillin-tazobactam induced thrombocytopenia. J Pharm Pract 28:204–206CrossRefGoogle Scholar
  10. 10.
    Loo AS, Gerzenshtein L, Ison MG (2012) Antimicrobial drug-induced thrombocytopenia: a review of the literature. Semin Thromb Hemost 38:818–829CrossRefGoogle Scholar
  11. 11.
    Chen H, Fan Z, Guo F, Yang Y, Li J, Zhang J et al (2016) Tazobactam and piperacillin-induced thrombocytopenia: a case report. Exp Ther Med 11:1223–1226CrossRefGoogle Scholar
  12. 12.
    Leger RM, Arndt PA, Garratty G (2008) Serological studies of piperacillin antibodies. Transfusion 48:2429–2434CrossRefGoogle Scholar
  13. 13.
    Bang NU, Kammer RB (1983) Hematologic complications associated with beta-lactam antibiotics. Rev Infect Dis 5(2 Suppl):S380–S393CrossRefGoogle Scholar
  14. 14.
    Greinacher A, Selleng K (2010) Thrombocytopenia in the intensive care unit patient. ASH Educ Progr 2010:135–143Google Scholar
  15. 15.
    Pérez-Vázquez A, Pastor JM, Riancho JA (1998) Immune thrombocytopenia caused by piperacillin/tazobactam. Clin Infect Dis 27:650–651CrossRefGoogle Scholar
  16. 16.
    Yan MT, Chu HY, Chau T, Lin SH (2009) Profound thrombocytopenia associated with piperacillin in a hemodialysis patient. Clin Nephrol 72:240–243CrossRefGoogle Scholar
  17. 17.
    Alzahrani M, Alrumaih I, Alhamad F, Abdel Warith A (2018) Rapid onset sudden thrombocytopenia following reexposure to piperacillin-tazobactam: report of two cases and review of the literature. Platelets 29:628–631CrossRefGoogle Scholar
  18. 18.
    Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239–245CrossRefGoogle Scholar
  19. 19.
    Wazny LD, Ariano RE (2000) Evaluation and management of drug-induced thrombocytopenia in the acutely ill patient. Pharmacotherapy 20:292–307CrossRefGoogle Scholar
  20. 20.
    Mohammadi M, Jahangard-Rafsanjani Z, Sarayani A, Hadjibabaei M, Taghizadeh-Ghehi M (2017) Vancomycin-induced thrombocytopenia: a narrative review. Drug Saf 40:49–59CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Caroline Beaulieu
    • 1
    Email author
  • Lisa Kurczewski
    • 1
  • Vishal Yajnik
    • 2
  1. 1.Department of PharmacyVirginia Commonwealth University HealthRichmondUSA
  2. 2.Department of AnesthesiologyVirginia Commonwealth University Health/Medical College of Virginia HospitalsRichmondUSA

Personalised recommendations